ABSTRACT
Preimplantation genetic testing for aneuploidies (PGT-A) analyzes the chromosomal status of the embryo before transfer, only chromosomally normal embryos are replaced into the uterus. By enabling the selection and transfer of euploid embryos, PGT-A can be used not only to increase implantation rates and pregnancy rates in infertile patients, but also to reduce the number of miscarriages and minimize the risk of having aneuploid offspring. Although the risk of having a live birth with a chromosomal aberration is low following PGT-A, the risk is not zero. The value of PGT-A has come under debate, as none of the randomized studies assessing PGT-A showed a clear benefit. However, the negative results may be at least partially attributable to the technical limitations of the cytogenetic technique employed in past studies: fluorescence in situ hybridization. Increasing evidence supports the use of PGT-A in idiopathic recurrent pregnancy loss patients.
